Latest Breaking News On - Covaxin trial result - Page 1 : comparemela.com

COVAXIN phase 3 full trial data will be made public in July: Bharat Biotech

COVAXIN phase 3 full trial data will be made public in July: Bharat Biotech ANI | Updated: Jun 09, 2021 17:44 IST By Shalini Bhardwaj New Delhi [India], June 9 (ANI): Hyderabad-based vaccine manufacturer Bharat Biotech, which is carrying out its phase 3 trial will publish the data in July following that the company will be applying for the full licensure of COVAXIN. It is critical to understand, and further emphasise the Phase-3 data will first be submitted to Central Drugs Standard Control Organisation (CDSCO), followed by peer-reviewed journals, with a timeline of 3 months for publication, and as communicated earlier COVAXIN® phase 3 results full trial data will be made public during July. Once data from the final analysis of phase III studies are available, Bharat Biotech will apply for full licensure for COVAXIN®, Bharat Biotech informed ANI on Wednesday.

Andhra pradeshNew delhiShalini bhardwajCentral drugs standard control organisationBharat biotechJapanese encephalitisCovaxin trial resultCovid vaccineஆந்திரா பிரதேஷ்புதியது டெல்ஹிமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்பாரத் பயோடெக்

According to some officials the Covaxin makers, Bharat Biotech, is likely to announce the results of the Phase 3 analysis in June

According to some officials the Covaxin makers, Bharat Biotech, is likely to announce the results of the Phase 3 analysis in June
swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.

India generalAndhra pradeshSanjay raiWorld health organizationIndia institute of medical sciencesBharat biotechAll india instituteMedical sciencesHindustan timesCovaxin efficacyCovaxin trialCovaxin trial resultIndia vaccineCovid 19 vaccineVaccine efficacyVaccine news

COVAXIN India indigenous vaccine has drawn global attention: ICMR

URL copied India s indigenous vaccine COVAXIN has drawn global attention: ICMR The Indian Council of Medical Research (ICMR) has said that Covaxin has drawn global attention. Covaxin is a COVID-19 vaccine being developed by ICMR-Bharat Biotech. It is now undergoing phase-3 trials. The ICMR in a tweet said that India s indigenous vaccine has achieved remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet s interest in publishing them. Encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites, the ICMR said.

New delhiSanjayk raiCentre for community medicineIndian council of medical researchIndia institute of medical sciencesImage sourceIndian councilMedical researchAll india instituteMedical sciencesBharat biotechCommunity medicineCovaxin resultsCovaxin productionCovaxin phase 3 trialCovaxin trial result